How MIEBO may help
MIEBO is an FDA-approved prescription eye drop that’s been studied in over 600 people. Keep reading to see the proven results of MIEBO.
In clinical studies, MIEBO
was shown to:
Significantly reduce
signs of dry eye*
With continued use of MIEBO, doctors saw improvements in the damage on the surface of the eye.
*MIEBO was studied against saline in 2 clinical trials of more than 1200 patients who were treated 4 times per day.
In clinical studies, MIEBO
was shown to:
Significantly reduce
symptoms of dry eye*
People in the studies felt their eye dryness significantly improved.
*MIEBO was studied against saline in 2 clinical trials of more than 1200 patients who were treated 4 times per day.
Dry eye relief in as little as 2 weeks
In the studies, doctors checked the signs and symptoms of dry eye after 2 weeks, and again after 8 weeks. Patients saw significant improvement at both checkpoints while they were continuing to use MIEBO.
Side effects with MIEBO are uncommon
MIEBO is a prescription eye drop approved by the FDA. Because it’s a prescription, it was studied in-depth in patients, unlike over-the-counter artificial tears.
The safety of MIEBO was studied in more than 600 people in 2 clinical trials that lasted 57 days (GOBI and MOJAVE). No serious side effects were seen in either study. The data below is an average of the studies.
0
Serious side effects
No one treated with MIEBO experienced serious side effects.
0.5%
felt burning or stinging
Very few people reported burning or stinging when putting in MIEBO (GOBI: 3 people; MOJAVE: 0 people).
0.2%
stopped using MIEBO due to side effects
Of the 614 people studied, only 1 person stopped using MIEBO because of side effects (GOBI: 1 person; MOJAVE: 0 people).
2.1%
reported blurred vision
The most common side effect seen with MIEBO was blurred vision, which occurred in 2.1% of people. It usually resolved within minutes (GOBI: 9 people; MOJAVE: 4 people). 0.8% of people also experienced eye redness.
Get the MIEBO
patient guide
Learn about dry eye, tear evaporation, and how MIEBO can help.
Available in other languages:
Clinical studies
Expand all
- MIEBO is an FDA-approved prescription eye drop that's been studied in over 600 people. In clinical studies, MIEBO was shown to significantly reduce the signs—damage on the surface of the eye—and symptoms of dry eye. With continued use of MIEBO, doctors saw significant improvement in the damage on the surface of the eye. People in the studies felt their eye dryness significantly improved.
- In the studies, doctors checked the signs and symptoms of dry eye after 2 weeks, and again after 8 weeks. Patients saw significant improvement at both checkpoints, as those improvements continued and were maintained with continued use of MIEBO.
- In these studies (GOBI and MOJAVE), MIEBO was studied against saline in 2 clinical trials of more than 1200 patients. A total of 208 patients from the GOBI study went on to enroll in an open-label extension study, KALAHARI, that evaluated the long-term safety and efficacy of MIEBO for an additional 52 weeks.
- The studies took place from 2019 to 2022. GOBI lasted from December 2019 until March 2021. MOJAVE lasted from November 2020 until August 2021. KALAHARI then evaluated the long-term safety and efficacy of MIEBO for an additional 52 weeks.
How MIEBO works
MIEBO works differently
See how MIEBO protects against too much tear evaporation.
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- Do not use if you are allergic to MIEBO
- Remove contact lenses before using MIEBO and wait for at least 30 minutes before reinserting
- It is important to use MIEBO exactly as prescribed
- It is not known if MIEBO is safe and effective in children under the age of 18
- In pivotal trials, the most common eye side effect seen in studies was blurred vision (1% to 3% of patients reported blurred vision and eye redness)
Click here for full Prescribing Information for MIEBO.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
INDICATION
MIEBO® (perfluorohexyloctane ophthalmic solution) is used to treat the signs and symptoms of dry eye disease.
IMPORTANT SAFETY INFORMATION
- Do not use if you are allergic to MIEBO
- Remove contact lenses before using MIEBO and wait for at least 30 minutes before reinserting
- It is important to use MIEBO exactly as prescribed
- It is not known if MIEBO is safe and effective in children under the age of 18
- In pivotal trials, the most common eye side effect seen in studies was blurred vision (1% to 3% of patients reported blurred vision and eye redness)
Click here for full Prescribing Information for MIEBO.
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
